Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an Ordinary Share)
Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an Ordinary Share) (FMS): 6 pipeline candidates · 1 upcoming catalyst · 14 clinical trials. Updated within the last hour.
BioSniper Score
3-factor signal · derived from public data
N/A
N/A
Lead: Approved
6 candidates
1 upcoming, next in ~512d
N/A
A transparent, data-derived signal for Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an Ordinary Share)across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$12.6B
Cash
—
Quarterly Burn
—
Runway
—
Revenue
—
Cash Runway vs Catalysts
Upcoming catalyst timeline.
Pipeline (6 candidates)
| Drug | Phase |
|---|---|
| difelikefalin | Phase 3 |
| patiromer powder for | Phase 3 |
| patiromer powder for orals | Phase 3 |
| prosorba protein a immunoadsorption column | Approved |
| sodium chloride 0.9% in plastic container | Approved |
| sodium chloride 0.9% in plastic container | Approved |
Upcoming Catalysts (1)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
214
Total value held
$913.2M
| Holder | Shares | Value |
|---|---|---|
| pzena investment management llc | 15,052,822 | $339.6M |
| fiduciary management inc /wi/ | 4,462,106 | $100.7M |
| dodge & cox | 3,826,910 | $86.3M |
| morgan stanley | 2,484,810 | $56.1M |
| millennium management llc | 1,641,301 | $37.0M |
| brandes investment partners, lp | 1,610,849 | $36.3M |
| todd asset management llc | 1,296,543 | $29.3M |
| goldman sachs group inc | 818,002 | $18.5M |
| blackrock, inc. | 627,669 | $14.2M |
| point72 asset management, l.p. | 509,907 | $11.5M |
Showing top 10 of 214 institutional holders of Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an Ordinary Share). Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an Ordinary Share)'s pipeline?
Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an Ordinary Share) (FMS) has 6 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an Ordinary Share)'s lead drug candidate?
Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an Ordinary Share)'s most advanced tracked candidate is difelikefalin (Phase 3) for Uremic Pruritus; Pruritus.
What is Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an Ordinary Share)'s next catalyst?
Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an Ordinary Share)'s next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: KORSUVA" — expected November 12, 2027.
What is Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an Ordinary Share)'s market capitalization?
Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an Ordinary Share)'s market capitalization is approximately $12.6B.
Who is the CEO of Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an Ordinary Share)?
Ms. Helen Giza is the chief executive officer of Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an Ordinary Share) (FMS).
Get the full picture on Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an Ordinary Share)
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.